Literature DB >> 7419274

[Pharmacokinetic and clinical studies with sisomicin in paediatrics (author's transl)].

M Doerck, G Fricke, G Gruenwaldt, H M von Hattingberg, M Scheer.   

Abstract

Pharmakokinetic and clinical investigations were carried out with sisomicin, one of the newer aminoglycoside antibiotics, in 40 children aged from seven days to ten years. Serum concentrations were determined in 35 children 1/2, 1, 2, 4 and 6 hours after i. m. injection of 1.0 mg sisomicin/kg body weight. The average peak serum levels were 2.48 mg/l in children under three months and 3.58 mg/l in children between seven months and ten years. Renal elimination in newborns is delayed in comparison to older infants and children; the distribution volume of the central compartment diminishes with increasing age. The effect of these two counteracting tendencies is that renal clearance remains constant in the age groups investigated, however the frequency of drug administration must be adjusted according to age. During an average treatment period of ten days adequate serum concentrations between 3.1 mg/l and 6.2 mg/l one hour after injection could be achieved with dosages adjusted to age and body weight. Clinical results were good: 18 out of 20 children could be cured clinically, and 20 out of 21 isolated infectious agents were eliminated. There were no problems in local and systemic tolerance.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7419274     DOI: 10.1007/bf01641473

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  9 in total

1.  [Pharmacokinetics and clinical observations of sisomicin, a newly developed aminoglycoside derivative (author's transl)].

Authors:  H Lode; B Kemmerich; P Koeppe; H Langmaack
Journal:  Dtsch Med Wochenschr       Date:  1975-10-17       Impact factor: 0.628

2.  A rotating iterative procedure (RIP) for estimating hybrid constants in multi-compartment analysis on desk computers.

Authors:  H M von Hattingberg; D Brockmeier; G Kreuter
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

3.  Treatment of complicated urinary tract infections. Comparative study of sisomicin and gentamicin.

Authors:  P O Madsen; T B Kjaer; A Mosegaard
Journal:  Urology       Date:  1977-06       Impact factor: 2.649

4.  Sisomicin treatment of serious neonatal infections. A clinical and pharmacokinetic study.

Authors:  P Henriksson; N Svenningsen; G Kahlmeter; K Haeger
Journal:  Acta Paediatr Scand       Date:  1977-05

5.  Comparison of sisomicin and gentamicin in bacteriuric patients with underlying diseases of the urinary tract.

Authors:  J Klastersky; C Hensgens; M Gerard; D Daneau
Journal:  Antimicrob Agents Chemother       Date:  1975-06       Impact factor: 5.191

6.  Comparative activity of sisomicin, gentamicin, kanamycin, and tobramycin.

Authors:  J A Waitz; E L Moss; C G Drube; M J Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

7.  [Sisomicin versus gentamicin. A comparison of antibacterial and pharmacokinetic properties (author's transl)].

Authors:  P Naumann; H Rosin; E Reintjens; M Köhler
Journal:  Dtsch Med Wochenschr       Date:  1976-08-27       Impact factor: 0.628

8.  [Antimicrobial effectiveness of sisomicin. I: In vitro activity of sisomicin compared with gentamicin, tobramycin, amikacin and kanamycin (author's transl)].

Authors:  H H Schassan
Journal:  Infection       Date:  1976       Impact factor: 3.553

9.  [Pharmacokinetic investigations on sisomicin in children (author's transl)].

Authors:  L Weingärtner; U Sitka; R Patsch; J Richter
Journal:  Monatsschr Kinderheilkd       Date:  1978-08
  9 in total
  2 in total

Review 1.  Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use.

Authors:  P Noone
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

2.  Pharmacokinetic assessment of netilmicin in newborns and older children.

Authors:  T Bergan; H Michalsen
Journal:  Infection       Date:  1982       Impact factor: 3.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.